CLINICAL STAGE III GASTRIC CANCER AJCC V8

This study is comparing two treatment approaches for patients with a specific type of stomach or gastroesophageal junction cancer that has not spread widely. The goal is to see if using an immunotherapy drug (atezolizumab) combined with chemotherapy before and after surgery works…

This early-stage trial is testing a new drug called BAY 1895344, given alongside standard chemotherapy drugs, in people with advanced solid tumors that have spread. The main goal is to find the safest and most effective dose of this combination. Researchers are especially interes…

This early-stage study is testing a new combination of two drugs, sonidegib and pembrolizumab, for people with advanced solid tumors that have spread. The main goals are to find the safest dose of the combination and see if it helps shrink or control the cancer. The study is enro…

This early-stage trial is testing whether a shorter, 2-week course of combined chemotherapy and radiation before surgery is safe and effective for patients with operable stomach cancer. The study involves 25 participants and compares this shorter approach to the standard 5-week t…

This study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy drug (irinotecan) works better than the chemotherapy alone. It is for people with advanced stomach or esophageal junction cancer that has a specific genetic change (TP53 mutati…

This study is testing a new approach to prevent stomach cancer from returning to the abdominal cavity after surgery. During the operation, doctors will wash the abdomen with a warm chemotherapy solution. The goal is to kill any stray cancer cells left behind to prevent the cancer…

This study is testing a special recovery plan for patients having surgery for stomach cancer. The plan aims to help patients feel better faster by reducing pain and nausea, helping their digestive system work again, and shortening their hospital stay. Researchers are following 52…